The answer to this question has to do with your investment style.
News & Analysis: Novavax
After its impressive run since the year started, the vaccine maker's stock still has upside potential.
This analyst thinks Novavax’s stock has little upside left.
Novavax's Vaccine Just Scored $1.6 Billion From Operation Warp Speed. Here's What It Means for Investors.
With late-stage clinical development costs covered by the government's funds, Novavax is cleared for takeoff.
Both of these small-cap vaccine stocks are up big in 2020.
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”
Major benchmarks were mixed to start the day.
The funds will support the rapid development and mass production of the biotech's coronavirus vaccine candidate, NVX-CoV2373.
It's a small-cap biotech that specializes in vaccines.
Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.